The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of the combination of BKM120 and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM) or other refractory solid tumors.
Kent C. Shih
No relevant relationships to disclose
Peter Acs
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
Lowell L. Hart
No relevant relationships to disclose
Rebecca A. Kosloff
No relevant relationships to disclose
Ruth E. Lamar
No relevant relationships to disclose
John D. Hainsworth
No relevant relationships to disclose